Wire · opportunities
Teva wins FDA nod for monthly olanzapine shot that ends monitoring
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 October 2026 · Fusion42 review
Teva's long-acting schizophrenia treatment Weltruza, a monthly subcutaneous olanzapine shot that eliminates the need for post-injection monitoring, received FDA approval and is planned for U.S. launch soon.
This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it between 9 Oct 2026 and 13 Oct 2026.
◆ ◆ The Wire takeaway
Your schizophrenia drug now can reach patients without the costly and limiting three-hour monitoring after injection. This opens the US market for simpler dosing and better adherence, shifting competitive advantage towards treatments like Weltruza.
◆ Coverage
20 sources · first reported 9 Oct 2026 · latest 13 Oct 2026
◆ Topics